Nippon Life Global Investors Americas’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$77.2M Sell
64,390
-11,420
-15% -$11.7M 3.07% 7
2026
Q1
$69.7M Sell
75,810
-250
-0.3% -$253K 3.14% 8
2025
Q4
$81.7M Buy
76,060
+780
+1% +$746K 3.39% 7
2025
Q3
$57.4M Buy
75,280
+680
+0.9% +$506K 2.42% 11
2025
Q2
$58.2M Buy
74,600
+4,810
+7% +$3.74M 2.56% 12
2025
Q1
$57.6M Buy
69,790
+5,180
+8% +$4.31M 2.83% 10
2024
Q4
$49.9M Sell
64,610
-7,190
-10% -$5.95M 2.3% 13
2024
Q3
$63.6M Sell
71,800
-22,110
-24% -$19.9M 2.73% 10
2024
Q2
$85M Buy
93,910
+630
+0.7% +$504K 3.74% 6
2024
Q1
$72.6M Sell
93,280
-8,620
-8% -$6.13M 3.39% 5
2023
Q4
$59.4M Sell
101,900
-880
-0.9% -$514K 3.3% 8
2023
Q3
$55.2M Buy
102,780
+17,270
+20% +$8.9M 3.4% 7
2023
Q2
$40.1M Sell
85,510
-11,710
-12% -$4.91M 2.72% 8
2023
Q1
$33.4M Buy
97,220
+3,620
+4% +$1.22M 2.14% 9
2022
Q4
$34.2M Buy
+93,600
New +$33.2M 2.26% 8

Other funds holding LLY

Nippon Life Global Investors Americas's LLY Position: Q2 2026 in Review

Nippon Life Global Investors Americas reduced its Eli Lilly (LLY) stake by 15% in Q2 2026, selling an estimated $11.7M and leaving 64,390 shares worth $77.2M. The position accounts for 3.07% of the portfolio, ranked #7.

Nippon Life Global Investors Americas first reported a position in LLY in Q4 2022 and has held it in 15 quarters since. The position peaked at $85M in Q2 2024. 3,039 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Nippon Life Global Investors Americas held 64,390 shares of Eli Lilly worth $77.2M as of Q2 2026.
  • Nippon Life Global Investors Americas sold 11,420 Eli Lilly shares in Q2 2026, an estimated $11.7M.
  • Eli Lilly made up 3.07% of Nippon Life Global Investors Americas's portfolio in Q2 2026, its #7 holding.
  • Nippon Life Global Investors Americas first reported a position in Eli Lilly in Q4 2022 and has held it in 15 quarters since.
  • Nippon Life Global Investors Americas's Eli Lilly position peaked at $85M in Q2 2024.
  • 3,039 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Nippon Life Global Investors Americas's 13F filing for Q2 2026, filed 6 Aug 2026.